The University of North Texas Health Science Center (HSC) at Fort Worth will significantly expand a program that creates diversity in the medical and biomedical…
A group of oncology-focused researchers led by co-principal investigator Ashesh B. Jani, MD, professor of radiation oncology at Winship Cancer Institute at Emory University, revealed…
OneOncology, the platform for independent oncology practices, said today that partner practice physicians and other OneOncology experts will make 23 presentations across 12 different subject…
Bristol-Myers Squibb announced results from the Phase 2/3 RELATIVITY-047 trial, which showed that the fixed-dose combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, administered as…
Innovent and Eli Lilly jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination…
Dana-Farber Cancer Institute (Dara-Farber), one of the world’s top comprehensive cancer treatment and research sites in Boston, affiliated with Harvard Medical School, is actually ranked…
OneOncology, the private equity-backed national platform for independent community oncology practices, announced two new Board of Managers and shared with TrialSite the robust clinical trials…
An Orange County, California-based venture commercializing an AI-based, early cancer detection test from a simple blood draw recently announced they received a strategically important grant…
Back in January, TrialSite’s founder Daniel O’Connor spoke with Gary A. Ulaner, MD, PhD, FACNM, director of the Hoag Molecular Imaging and Therapy Program, about the emergence of Hoag Memorial…
University of California, San Francisco (UCSF) researchers focusing on immunotherapies that fight cancer center their attention on emerging engineered smart immune cells can zap solid…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
